Immunocore Holdings (IMCR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.02
- Estimate
- $0.03
- Surprise
- -175.9%
- Revenue (period 2026-06-30)
- $115.9M
- Score today
- 5.3/10
Revenue source: xbrl.
How the report landed
Immunocore Holdings (IMCR) reported a wider loss than forecast — diluted EPS of -$0.02 against the $0.03 estimate (a 175.9% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates IMCR Sell at 5.3/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -175.9% surprise compares with a -23.8% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Product: KIMMTRAK
- Concentration risk — Geographic: United States
- Quality below floor (2.5 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $32.60
- Price target
- $54.38
- Stop
- $31.51
- Upside to target
- +66.8%
- Reward-to-risk
- 9.8:1
Risk check: RSI 24 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
IMCR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.68B
- P/E (fwd)
- -43.4
- 52-week range
- $27.55–$40.72
- Off 52-week high
- 19.9%
- RSI (14)
- 24
- Volume vs avg
- 0.86×
- Score today
- 5.3/10